COVID-19 oral antivirals from Pfizer Inc. and Merck & Co., Inc. may face access restrictions because health plans and pharmacy benefit managers are providing dispensing fees that many pharmacies believe are inadequate to cover costs.
Pfizer’s Paxlovid (nirmatrelvir/ritonavir) and Merck’s molnupiravir were approved under US Food and Drug Administration emergency use authorizations in late December...







